Professor of Medicine, The Ohio State University Wexner Medical Center
Oncology
Dr. David P. Carbone, MD
|
|
Give Review
Doctor David P. Carbone, MD practices Oncology. He went to medical school at Johns Hopkins University School of Medicine. Johns Hopkins University School of Medicine is a top medical college. Johns Hopkins University School of Medicine is ranked 3 in research and 29 in primary care medicine He has 1 awards "Elected Member". David Carbone is a published MD. He has 100 papers published. The most current publication "Predictive markers for the efficacy of anti-PD-1/PD-L1 antibodies in lung cancer." David Carbone accepts Medicare.
Publications
- Predictive markers for the efficacy of anti-PD-1/PD-L1 antibodies in lung Cancer.
- Multivalent Forms of the Notch Ligand DLL-1 Enhance Antitumor T-cell Immunity in Lung Cancer and Improve Efficacy of EGFR-Targeted Therapy.
- Mechanisms of and strategies for overcoming resistance to anti-vascular endothelial growth factor therapy in non-small cell lung Cancer.
- EGFR Blockade Enriches for Lung Cancer Stem-like Cells through Notch3-Dependent Signaling.
- Early-Stage Lung Cancer: 40s Anniversary.
- LKB1 Loss Induces Characteristic Patterns of Gene Expression in Human Tumors Associated with NRF2 Activation and Attenuation of PI3K-AKT.
- Acquired Resistance of EGFR-Mutant Lung Adenocarcinomas to Afatinib plus Cetuximab Is Associated with Activation of mTORC1.
- An era of lung Cancer iconoclasts.
- Phase II Study of Bendamustine in Relapsed Chemotherapy Sensitive or Resistant Small-Cell Lung Cancer.
- Reducing lung Cancer mortality: 2014 update.
- Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously tre...
- The effect of IGF-I receptor blockade for human Esophageal squamous cell carcinoma and adenocarcinoma.
- ALDH7A1 expression is associated with recurrence in patients with surgically resected non-small-cell Lung carcinoma.
- Identifying barriers associated with enrollment of patients with lung Cancer into clinical trials.
- Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung Cancer treated with erlotinib or placebo in the NCIC Clinical...
- In-depth proteomic analysis of nonsmall cell lung Cancer to discover molecular targets and candidate biomarkers.
- A Double-Blind Randomized Discontinuation Phase-II Study of Sorafenib (BAY 43-9006) in Previously Treated Non-Small-Cell Lung Cancer Patients: Eastern Cooperative Onco...
- Sonic hedgehog pathway expression in non-small cell lung Cancer.
- Long-term smoking mediated down-regulation of Smad3 induces resistance to carboplatin in non-small cell lung Cancer.
- Effects of Cancer-associated EPHA3 mutations on lung Cancer.
- Tumour suppressor Fus1 provides a molecular link between inflammatory response and mitochondrial homeostasis.
- Added value of a serum proteomic signature in the diagnostic evaluation of Lung nodules.
- Leveling the playing field: bringing development of biomarkers and molecular diagnostics up to the standards for drug development.
- ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers.
- Smoking attenuates transforming growth factor-beta-mediated tumor suppression function through downregulation of Smad3 in lung Cancer.
- Insulin-like growth factor receptor expression is associated with aggressive phenotypes and has therapeutic activity in biliary tract Cancers.
- Role of insulin-like growth factor-1 signaling pathway in cisplatin-resistant lung Cancer cells.
- Elucidating the mechanism of regulation of transforming growth factor beta Type II receptor expression in human lung Cancer cell lines.
- Resuscitating Cancer immunosurveillance: selective stimulation of DLL1-Notch signaling in T cells rescues T-cell function and inhibits tumor growth.
- Delivering affordable Cancer care in high-income countries.
- Adjuvant therapy in non-small cell lung Cancer: future treatment prospects and paradigms.
- Translating Cancer complexity to clinical decisions.
- The efficacy of IGF-I receptor monoclonal antibody against human gastrointestinal carcinomas is independent of k-ras mutation status.
- Insulin-like growth factor-I receptor blockade reduces tumor angiogenesis and enhances the effects of bevacizumab for a human gastric Cancer cell line, MKN45.
- Methods for peptide and protein quantitation by liquid chromatography-multiple reaction monitoring mass spectrometry.
- Inhibition of JAK2 signaling by TG101209 enhances radiotherapy in lung Cancer models.
- Lung Cancer Diagnosis from Proteomic Analysis of Preinvasive Lesions.
- Genetic subunit vaccines : a novel approach for genetic immunization.
- Lung Cancer in 2010: One size does not fit all.
- A candidate targeting molecule of insulin-like growth factor-I receptor for gastrointestinal Cancers.
- MALDI-MS derived prognostic protein markers for resected non-small cell lung Cancer.
- Anti-vascular endothelial growth factor treatment in combination with chemotherapy delays hematopoietic recovery due to decreased proliferation of bone marrow hematopo...
- VeriStrat classifier for survival and time to progression in non-small cell lung Cancer (NSCLC) patients treated with erlotinib and bevacizumab.
- Deletion of IGF-I receptor (IGF-IR) in primary osteoblasts reduces GH-induced STAT5 signaling.
- Targeting for insulin-like growth factor-I receptor with short hairpin RNA for human digestive/gastrointestinal Cancers.
- Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in Cancer patients.
- Notch3 cooperates with the EGFR pathway to modulate apoptosis through the induction of bim.
- Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung Cancer in Eastern Cooperative Oncol...
- Targeting specific regions of the Notch3 ligand-binding domain induces apoptosis and inhibits tumor growth in lung Cancer.
- Prognostic factors for resected non-small cell lung Cancer with pN2 status: implications for use of postoperative radiotherapy.
- Integration of molecular profiling into the lung Cancer clinic.
- Profiles in variation: Lung carcinogenesis.
- Insulin-like growth factor-I receptor blockade reduces the invasiveness of gastrointestinal Cancers via blocking production of matrilysin.
- A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung Cancer.
- Phase I study of adenovirus p53 administered by bronchoalveolar lavage in patients with bronchioloalveolar cell Lung carcinoma: ECOG 6597.
- Adenosine receptors in regulation of dendritic cell differentiation and function.
- Host A(2B) adenosine receptors promote carcinoma growth.
- Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas.
- Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer.
- Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.
- Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis.
- Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung Cancer.
- Cytoplasmic clusterin expression is associated with longer survival in patients with resected non small cell lung Cancer.
- Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung Cancers.
- Advances and challenges in aerodigestive epithelial Cancer: meeting summary and research opportunities.
- Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF.
- Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaGlandin dehydrogenase in non-small-cell lung cancer.
- Mass spectrometry to classify non-small-cell lung Cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors...
- Insulin-like growth factor-I receptor as a marker for prognosis and a therapeutic target in human Esophageal squamous cell carcinoma.
- Phase I study of Paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced non-small cell lung Cancer.
- Adenovirus expressing shRNA to IGF-1R enhances the chemosensitivity of lung Cancer cell lines by blocking IGF-1 pathway.
- PDGFR-beta expression in small cell lung Cancer patients.
- Proteomics analysis in lung Cancer: challenges and opportunities.
- Genomics and proteomics: emerging technologies in clinical Cancer research.
- Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung Cancer.
- Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism.
- Selective profiling of proteins in lung Cancer cells from fine-needle aspirates by matrix-assisted laser desorption ionization time-of-flight mass spectrometry.
- Analysis of host- and tumor-derived proteinases using a custom dual species microarray reveals a protective role for stromal matrix metalloproteinase-12 in non-small c...
- Thioredoxin-1 modulates transcription of cyclooxygenase-2 via hypoxia-inducible factor-1alpha in non-small cell lung Cancer.
- In vivo imaging of adenovirus transduction and enhanced therapeutic efficacy of combination therapy with conditionally replicating adenovirus and adenovirus-p27.
- Proteomic patterns of preinvasive bronchial lesions.
- Restoration of TGF-beta signalling reduces tumorigenicity in human lung Cancer cells.
- Biomarkers of response to gefitinib in non-small-cell lung Cancer.
- Targeting cyclooxygenase-2 in recurrent non-small cell lung Cancer: a phase II trial of celecoxib and docetaxel.
- Immunization with mutant p53- and K-ras-derived peptides in Cancer patients: immune response and clinical outcome.
- Cloned fusion product from a rare t(15;19)(q13.2;p13.1) inhibit S phase in vitro.
- Dominant-negative Notch3 receptor inhibits mitogen-activated protein kinase pathway and the growth of human lung Cancers.
- Insulin-like growth factor I receptor blockade enhances chemotherapy and radiation responses and inhibits tumour growth in human gastric Cancer xenografts.
- Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell Lung carcinoma.
- Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor ...
- VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression.
- Constitutive activation of Notch3 inhibits terminal epithelial differentiation in Lungs of transgenic mice.
- Improving the evaluation of new Cancer treatments: challenges and opportunities.
- Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaGlandin EP2 receptor.
- Recombinant adenoviruses expressing dominant negative insulin-like growth factor-I receptor demonstrate antitumor effects on lung Cancer.
- Effects of genetic blockade of the insulin-like growth factor receptor in human colon Cancer cell lines.
- H1(0) histone and differentiation of dendritic cells. A molecular target for tumor-derived factors.
- Genetic and immunologic therapies for lung Cancer.
- Immune dysfunction in Cancer patients.
Schools
Johns Hopkins University School of Medicine
Johns Hopkins
National Canc Institute
Conditions Treated
- Adrenal Gland Cancer
- Anemia
- Bladder Cancer
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Elected Member
Education
-
Johns Hopkins University -
Johns Hopkins University School of Medicine
Hospital
-
Vanderbilt Hospital and Clinics -
Ohio State University Wexner Medical Center
Drug Facts
| NPI NUMBER | 1558453977 | |
| NPPES Provider LastName | CARBONE | |
| NPPES Provider FirstName | DAVID | |
| NPPES Provider ZIPCode | 432101280 | |
| NPPES Provider State | OH | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 77.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1558453977 |
| Last Name Of The Provider | CARBONE |
| First Name Of The Provider | DAVID |
| View All |
Similar Doctors
|
Dr. Charles L. Shapiro, MD |
|
Dr. Anterpreet Neki, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Kari L. Kendra, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gregory A. Otterson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Taral Patel, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Guido Marcucci, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Maura L. Gillison, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Drew R. Oostra, MD
This Doctor is OpenDoctor Recommended.
|